logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Pralsetinib for RET-fusion positive metastatic non-small-cell lung cancer

< Back

Pralsetinib for RET-fusion positive metastatic non-small-cell lung cancer

Drugs

Cancer and Palliative Care

September 2020


Pralsetinib is in clinical development for the treatment of metastatic RET-fusion positive non-small cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer and at the metastatic stage the disease has already spread from the lungs to other sites. Around 2% of these patients will have tumours that contain fusion mutations in the RET gene. Cells in these tumours allow uncontrolled cancer growth. There are currently no therapies recommended for the treatment of NSCLC with a RET mutation.

Pralsetinib is an investigational, once-daily oral precision therapy designed to selectively target, and potentially inhibit, RET mutations, regardless of the tissue of origin. If licensed, pralsetinib will offer a treatment option for adult patients with RET-fusion positive advanced NSCLC, who currently have no highly selective therapies available.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts